Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I. Schernthaner G, et al. Among authors: karasik a. Diabetes Res Clin Pract. 2019 Jul;153:30-40. doi: 10.1016/j.diabres.2019.05.013. Epub 2019 May 20. Diabetes Res Clin Pract. 2019. PMID: 31121272 Free article.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
Schernthaner G, Lehmann R, Prázný M, Czupryniak L, Ducena K, Fasching P, Janež A, Karasik A, Kempler P, Martinka E, Shestakova MV, Duvnjak LS, Tankova T. Schernthaner G, et al. Among authors: karasik a. Cardiovasc Diabetol. 2017 Oct 23;16(1):137. doi: 10.1186/s12933-017-0622-7. Cardiovasc Diabetol. 2017. PMID: 29061170 Free PMC article. Review.
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Schernthaner G, Karasik A, Abraitienė A, Ametov AS, Gaàl Z, Gumprecht J, Janež A, Kaser S, Lalić K, Mankovsky BN, Moshkovich E, Past M, Prázný M, Radulian G, Smirčić Duvnjak L, Tkáč I, Trušinskis K. Schernthaner G, et al. Among authors: karasik a. Cardiovasc Diabetol. 2019 Aug 31;18(1):115. doi: 10.1186/s12933-019-0920-3. Cardiovasc Diabetol. 2019. PMID: 31472683 Free PMC article.
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Among authors: karasik a. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.
Lyu B, Sang Y, Selvin E, Chang AR, Alexander GC, Cohen CM, Coresh J, Shalev V, Chodick G, Karasik A, Carrero JJ, Fu EL, Xu Y, Grams ME, Shin JI. Lyu B, et al. Among authors: karasik a. Diabetes Care. 2022 Dec 1;45(12):2926-2934. doi: 10.2337/dc22-1253. Diabetes Care. 2022. PMID: 36282149 Free PMC article.
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: karasik a. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Free article. Clinical Trial.
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Schechter M, Melzer Cohen C, Fishkin A, Rozenberg A, Yanuv I, Sehtman-Shachar DR, Chodick G, Clark A, Abrahamsen TJ, Lawson J, Karasik A, Mosenzon O. Schechter M, et al. Among authors: karasik a. Cardiovasc Diabetol. 2023 May 27;22(1):126. doi: 10.1186/s12933-023-01829-0. Cardiovasc Diabetol. 2023. PMID: 37244998 Free PMC article.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: karasik a. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
216 results